SARS-CoV-2免疫血清学与疫苗接种状态与心肌梗死严重程度及结局的关联
单中心回顾性队列研究纳入949例1型心肌梗死患者,分析既往SARS-CoV2疫苗接种及血清状态与梗死严重程度及结局的关联。
要点
- 该组SARS-CoV-2 S特异性IgG滴度最高(中位数>2080 AU/mL,IQR 1560->2080),未接种组为91(32-198)。
核心结论
- 疫苗接种合并自然SARS-CoV2感染与STEMI患者发生严重心力衰竭和心源性休克相关,可能与血清学反应增强有关。
研究设计与样本
- 单中心回顾性队列研究,2020年3月1日至2023年3月1日纳入949例1型心肌梗死患者,其中STEMI 656例、NSTEMI 293例,平均年龄64岁(SD 13),80%为男性。
主要发现
- 入院前疫苗接种状态:≥1剂占53%,完全接种占49%,第一剂加强针占25%;所接种疫苗中84%为mRNA疫苗。
- 心肌梗死后6个月,92例(9.7%)发生主要不良心血管事件(MACE),50例死亡;STEMI后11%患者出现严重心力衰竭或心源性休克(Killip III-IV级)。
- 该组SARS-CoV-2 S特异性IgG滴度最高(中位数>2080 AU/mL,IQR 1560->2080),未接种组为91(32-198)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic adversely affected the severity and prognosis of patients with acute myocardial infarction (MI) caused by atherothrombosis (type 1 MI). The effect, if any, of COVID-19 vaccination and natural SARS-CoV2 serologic immunity in these patients is unclear. Our aim was to analyze the association between the severity and outcome of patients with type 1 MI and their previous SARS-CoV2 vaccination and serostatus. METHODS: A single-center retrospective cohort study conducted between March 1, 2020 and March 1, 2023. Clinical and follow-up information was collected from medical records and patients. Total antibodies (IgM, IgA, IgG) to nucleocapsid (N) antigens were measured by ECLIA (electrochemiluminescence-based immunoassay) to test the immune response to natural infection. If positive, IgM and IgG antibodies to spike (S) surface antigens were measured by CLIA to test the immune response to vaccine or natural infection. Multivariable logistic regression analysis was performed, adjusting for age, sex, hypertension, diabetes, and dyslipidemia. RESULTS: Total sample of 949 patients, 656 with ST-segment elevation MI (STEMI) and 293 with non-ST-segment elevation MI (NSTEMI). Mean age was 64 (SD 13) years, 80 % men. Pre-admission vaccination status was: ≥ 1 dose, 53 % of patients; complete vaccination, 49 %; first booster dose, 25 %. The majority (84 %) of vaccines administered were mRNA-based. Six months after MI, 92 (9.7 %) patients had a major adverse cardiac event (MACE) and 50 died; 11 % of patients had severe heart failure or cardiogenic shock (Killip III-IV) after STEMI. Vaccinated patients with STEMI and positive serology (Pos/Vax group) had a higher risk of Killip III-IV on admission: OR 2.63 (1.27-5.44), p = 0.010. SARS-CoV-2 S-specific IgG titers were highest in this group (median > 2080 AU/mL, [IQR 1560- >2080] vs 91 [32-198] in the unvaccinated group). In the overall sample, a higher incidence of 6-month MACE was not demonstrated (OR 1.89 [0.98-3.61], p = 0.055). CONCLUSIONS: The combination of vaccination and natural SARS-CoV2 infection was associated with the development of severe heart failure and cardiogenic shock in patients with STEMI, possibly related to an increased serological response.
引用
- Blasco A, Royuela A, García-Gómez S, et al. Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome. Vaccine. 2024. PMID: 39244425. doi:10.1016/j.vaccine.2024.126305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。